Decoy Therapeutics
DCOY
27 hedge funds and large institutions have $10.7M invested in Decoy Therapeutics in 2021 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
17% more funds holding
Funds holding: 23 → 27 (+4)
0% less ownership
Funds ownership: 0% → 0% (-0%)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
53% less capital invested
Capital invested by funds: $22.8M → $10.7M (-$12.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$623K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$222K |
| 3 |
BlackRock
New York
|
+$178K |
| 4 |
State Street
Boston,
Massachusetts
|
+$178K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$178K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$2.18M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$1.87M |
| 3 |
ACM
Altium Capital Management
New York
|
-$1.85M |
| 4 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$1.2M |
| 5 |
MS
Maven Securities
St Helier,
Jersey
|
-$756K |
DCOY Hedge Fund Activity: Q2 2021 in Review
27 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q2 2021, worth a combined $10.7M — down 53% from $22.8M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new DCOY positions and 4 closed out — a net gain of 4 holders — while 4 added to existing stakes and 6 trimmed.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $623K. The largest seller was Sio Capital Management, cutting an estimated $2.18M.
- 27 institutional investors held Decoy Therapeutics (DCOY) as of Q2 2021, up from 23 in Q1 2021.
- Funds reported $10.7M of Decoy Therapeutics stock for Q2 2021, down 53% quarter-over-quarter.
- 8 funds opened new Decoy Therapeutics positions in Q2 2021 and 4 closed out, a net change of +4 holders.
- The largest Decoy Therapeutics buyer in Q2 2021 was Morgan Stanley, an estimated $623K added.
- The largest Decoy Therapeutics seller in Q2 2021 was Sio Capital Management, an estimated $2.18M sold.
Based on aggregated 13F filings for Q2 2021.